Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790246 | Urologic Oncology: Seminars and Original Investigations | 2017 | 9 Pages |
Abstract
Based on results of the IMvigor 210 clinical trial, the anti-programmed death-ligand1 antibody atezolizumab gained regulatory approval in May 2016 for use in locally advanced and metastatic UC in patients with progression of disease despite prior platinum-based chemotherapy. Since that time, additional CPIs (avelumab, durvalumab, nivolumab, and pembrolizumab) have gained regulatory approval in the postplatinum setting. The approval of pembrolizumab was supported by KEYNOTE-045, the first reported randomized, phase III trial of a CPI in UC. Atezolizumab and pembrolizumab are also approved for first-line therapy for cisplatin-ineligible patients with locally advanced or metastatic disease. The rapid expansion of therapeutic options in UC has shifted the treatment paradigm.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Benjamin A. M.D., Tianfang He, Janaki M.D., Guru M.D.,